Daily Statin Cuts Cardiovascular Risk in HIV Daily Statin Cuts Cardiovascular Risk in HIV
Final data from the REPRIEVE trial show pitavastatin therapy is associated with a significantly lower risk of cardiovascular events than placebo as evidence grows for statins in primary prevention.Medscape Medical News
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Heart | HIV AIDS | Infectious Diseases | Statin Therapy